Anti-CD20 Bispecifics Could Find Niche In First-Line Lymphoma

Highly Entrenched Rituxan Could Prove Tough To Dislodge

Cancer-cells-pink-color_1200x675
Roche presented data at ASCO on its two CD20xCD3-targeting bispecific antibodies • Source: Shutterstock

More from ASCO

More from Conferences